2 completed, 1 withdrawn. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow Trientine: new trials by email Literature Review of Trientine trials Research Report on Trientine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy Trientine, Placebo - Hypertrophic Cardiomyopathy | Phase 2 | Completed | Manchester University NHS Foundation Trust | 154 | 2020-12-01 | 2025-09-29 |
| Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer trientine dihydrochloride, pegylated liposomal doxorubicin, carboplatin - Ovarian Neoplasms Malignant (Excl Germ Cell), Peritoneal Carcinoma | Phase 1 / Phase 2 | Completed | National Cheng-Kung University Hospital | 18 | 2012-09-01 | 2020-11-10 |
| Trientine Hydrochloride for the Prevention of Macular Edema After Cataract Surgery in Patients With Type 2 Diabetes Mellitus Trientine Hydrochloride, For Arm B there is no therapeutic intervention other than standard of care, which is cataract surgery. - Macular Edema Following Cataract Surgery | Phase 2 | Withdrawn | University of British Columbia | 2018-05-09 |
Carcinoma, Ovarian Epithelial (1) · Cardiomyopathy, Hypertrophic (1) · Fallopian Tube Neoplasms (1) · Macular Edema (1)
Manchester University NHS Foundation Trust (1) · National Cheng-Kung University Hospital (1) · University of British Columbia (1)
Canada (1) · United Kingdom (1)
Chris Miller (1) · David Maberley, MD,FRCSC,MSc(Epid) (1)